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Background The increasing number of transcatheter aortic valve implantation (TAVI) in the last few years has unveiled a unique
set of events and complications that need prompt recognition and management in order to improve patient out-
comes, often involving a multidisciplinary team.
...................................................................................................................................................................................................
Case summary We present a case of a 86-year-old woman with symptomatic severe aortic stenosis that underwent a TAVI and,
in the post-procedure period, presented with acute abundant haematemesis, haemodynamic instability, and haemo-
globin drop. The diagnosis of acute necrotizing oesophagitis (ANE) was made by upper gastrointestinal endoscopy.
...................................................................................................................................................................................................
Discussion Acute necrotizing oesophagitis is a rare entity caused usually by an ischaemic insult in the presence of predisposing
factors; it has a high rate of complications and mortality. To the best of our knowledge, this is the first clinical case
report to describe the occurrence of ANE as a possible complication of TAVI and is also an example of the im-
portance of the multidisciplinary approach of these complex patients, which extends even beyond the concept of
Heart Team.
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Learning points
• As the number of transcatheter aortic valve implantation (TAVI) has increased in the last decade, a unique set of post-intervention events
and complications have been identified.
• This is the first clinical case report to describe the occurrence of acute necrotizing oesophagitis (ANE) as a possible complication of TAVI.
• Transcatheter aortic valve implantation patients are prone to ANE due to their advanced age and frailty, comorbidities, ischaemic insult,
and anti-platelet therapy.
• Acute necrotizing oesophagitis is a rare entity with high rate of acute and long-term complications and successful management requires
early detection and multidisciplinary care.
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..Introduction
Transcatheter aortic valve implantation (TAVI) has revolutionized
the management of aortic stenosis in the last decade.1 However, as
the number of TAVI has increased, a unique set of post-intervention
events and complications have been identified. Bradyarrhythmias,
vascular access complications, acute cerebral vascular accidents,
acute renal failure, cardiac tamponade, aortic root rupture, and aortic
regurgitation are some of the most common described complica-
tions.2–5 Their recognition is critical to improve patients’ outcomes,
often involving a multidisciplinary team. In the present article, we re-
port the occurrence of acute necrotizing oesophagitis (ANE), an
undescribed complication possibly associated with TAVI.
Timeline
Case presentation
We present the case of an 86-year-old woman with a past medical
history of endometrial cancer, treated by hysterectomy, oophorec-
tomy and radiotherapy, and with consequent radiation cystitis; she
also had dyslipidaemia and osteoporosis, associated with thoracic ky-
phosis, chronic back pain and mobility impairment (need of walking
stick support, help with daily activities and house-keeping). The pa-
tient presented with fatigue on moderate exertion with progressive
aggravation in the last 4 months. On cardiac auscultation, a mid-
systolic murmur was audible along the upper right sternal border.
The electrocardiogram revealed sinus rhythm with left axis deviation
and repolarization abnormalities (Figure 1). Transthoracic echocardi-
ography (TTE) revealed: left ventricular (LV) concentric hypertrophy
(LV mass index of 123 g/m2; relative wall thickness of 0.49); non-
dilated LV (end-diastolic volume of 45 mL/m2), normal ejection frac-
tion (57%), and diastolic dysfunction (e/a ratio of 0.5; e/e0 of 13; left
atrium volume index of 44 mL/m2; and tricuspid regurgitation velocity
of 2.9 m/s); ascending aorta dilatation (49 mm); tricuspid aortic valve,
severely calcified, with severe stenosis (sAS)—mean gradient of
52 mmHg and valve area of 0.87 cm2. Blood tests showed N-terminal
prohormone of brain natriuretic peptide of 1302 pg/mL (0–300 pg/
mL), without other significant abnormalities (Table 1). Coronary angi-
ography was normal. Due to symptomatic sAS, the case was dis-
cussed in Heart Team, in order to decide the best approach to aortic
valve replacement. Considering the advanced age, moderate frailty
(Clinical Frailty Scale assessment of 6,5 normal body mass index of
22 kg/m2), restricted mobility, and intermediate surgical risk [Society
of Thoracic Surgeons (STS) score: 4.2% risk of mortality], TAVI was
considered the best option. Pre-TAVI computed tomography angiog-
raphy was performed to determine the best vascular access and the
appropriate dimensions of the aortic valve prosthesis. It confirmed
dilatation of the ascending aorta (50 mm) and diffuse atherosclerotic
....................................................................................................................................................................................................................
Time Description of relevant clinical information Intervention required
December 2016 Evaluation in outpatient clinic: complains of fatigue on moderate ex-
ertion in the last 4 months.
Performing of diagnostic tests in ambulatory.
January 2017 Severe aortic valve stenosis diagnosis (mean gradient of 52 mmHg
and valve area of 0.87 cm2).
Discussion in Heart Team.
March 2017 Accepted to transcatheter aortic valve implantation (TAVI). TAVI scheduling.
Day 0 TAVI procedure, transfemoral approach, without acute
complications.
Admission to intensive care unit.
Dual antiplatelet therapy (DAPT) initiation.
Day 1 Favourable evolution (without access complications or rhythm dis-
turbances and with haemodynamic stability).
Day 2 Acute abundant haematemesis, haemodynamic instability, and
haemoglobin drop.
Endoscopy showed lesions compatible with acute
necrotizing oesophagitis diagnosis.
Fluid therapy and replacement of blood products.
Proton-pump inhibitor (IBP) therapy, domperidone and
sucralfat.
DAPT suspended.
Day 3 Haematemesis in small quantity. Therapeutic maintenance.
Day 4 Favourable evolution, with haemodynamic stabilization and without
haematemesis.
Therapeutic maintenance.
Day 5 Endoscopy showing resolution of the previously described lesions. Oral diet was progressively initiated.
Day 6 IBP was switched to oral formulation.
Day 7 DAPT was re-instituted.
Day 8 Patient was discharged clinically well and without any symptoms.
August 2017 Follow-up in outpatient clinic, without symptoms or complications.
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Figure 1 Patient’s electrocardiogram on admission: sinus rhythm with left axis deviation and repolarization abnormalities.
....................................................................................................................................................................................................................
Table 1 Blood tests results
Parameters (unit) Pre´-TAVI First day
Post-TAVI
Second day
Post-TAVI
Fourth day
Post-TAVI
At discharge Normal range
Haemoglobin (g/dL) 12.7 11.4 9.6 9.9 10.4 12–15.3
Leucocytes (109/L) 4.0 6.5 3.04 3.0 3.0 4.0–11.0
Platelets (109/L) 181 115 119 146 170 150–450
Partial thromboplastin time (s) 27.3 31.0
Prothrombin time (s) 11.3 11.6
Urea (mg/dL) 52 48 36 22 21 16–49
Creatinine (mg/dL) 0.99 0.9 0.89 0.75 0.83 0.51–0.95
Sodium (mmol/L) 139 140 143 139 139 135–145
Potassium (mmol/L) 4.8 4.1 3.9 3.8 4.2 3.5–5.1
C-reactive protein (mg/dL) 0.09 7.49 7.55 2.4 1.51 <0.5
Aspartate aminotransferase (U/L) 18 16 13 15 0–32
Alanine aminotransferase (U/L) 6 6 5 5 0–33
Gamma glutamyl transferase (U/L) 12 9 9 0–40
Alkaline phosphatase (U/L) 99 63 65 35–105
Bilirubin (mg/dL) 0.32 0.32 <1.2
NTproBNP (pg/mL) 1302 580 <300
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..disease, without any obstructive lesions. Elective transfemoral TAVI
was scheduled.
The procedure was performed under general anaesthesia and
guided by transoesophageal echocardiogram (TOE), via the right
femoral route. Balloon valvuloplasty (20 40 mm balloon) was per-
formed prior to aortic valve prosthesis implantation (Edwards
Sapiens 3TM, 23 mm, through a NovaFlexTM delivery system).
Valvuloplasty and prosthesis deployment were accomplished during
a burst of rapid ventricular pacing, using a temporary pacemaker,
with 30–40 s of intentional low cardiac output state—systolic blood
pressure (SBP) of 40–50 mmHg. After valve deployment, the patient
presented a short period of hypotension (SBP 60–70 mmHg and dia-
stolic blood pressure ±20 mmHg; heart rate ±100 b.p.m.), with spon-
taneous recovery in less than 3 min. The final result was satisfactory,
with a slight leak in relation to the native left coronary cusp, a max-
imum transvalvular gradient of 12 mmHg, and a mean gradient of
5.3 mmHg. The patient was extubated at the end of the procedure
and was admitted to the intensive care unit, with maintained haemo-
dynamic stability and on spontaneous ventilation. Dual antiplatelet
therapy (DAPT)—acetylsalicylic acid 100 mg and clopidogrel
75 mg—was initiated, in addition to the patient’s usual medication
(otilonium bromide, trospium chloride, nitrofurantoin, simvastatin,
risedronate, calcium, and vitamin D).
Despite the favourable initial evolution, during the second day after
TAVI the patient presented with acute abundant haematemesis (cof-
fee ground colour vomitus) associated with hypotension (decrease
of SBP from 130 mmHg to 90 mmHg) and haemoglobin drop from
12.7 g/dL to 9.6 g/dL (12–15.5 g/dL). C-reactive protein was slightly
elevated (7.55 mg/dL; reference range 0–0.5 mg/dL), as usual follow-
ing an invasive procedure (Table 1). Intravenous pantoprazole infu-
sion was administered, the patient was kept nil by mouth, intensive
crystalloid fluid therapy was initiated, and an emergency upper
gastrointestinal endoscopy was performed. Endoscopy showed strik-
ing diffuse, circumferential, black-appearing oesophageal mucosa with
signs of friability, and under-distension of the lumen, involving the dis-
tal oesophagus (Figure 2). These findings were compatible with ANE,
also known as black oesophagus. Accordingly, haemodynamic stabil-
ization measures (fluid therapy and replacement of blood products)
and proton-pump inhibitor (PPI) therapy were maintained, domperi-
done and sucralfat were initiated, and DAPT was temporarily sus-
pended. Haematemesis stopped and the patient was stabilized 48 h
after the acute event. Computed tomography angiography was
Figure 2 Endoscopy showing striking diffuse, circumferential, black-appearing oesophageal mucosa with signs of friability, involving the distal oe-
sophagus. These findings are compatible with acute necrotising oesophagitis, also known as black oesophagus.
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performed to evaluate any abnormality in oesophageal vasculariza-
tion or aortic lesion and to exclude complications: it showed wall
thickness of lower oesophagus with mucosal enhancement and
densification of perioesophageal fat, without other abnormalities.
Upper endoscopy was repeated 72 h later, showing resolution of the
previously described lesions (Figure 3). Afterwards, oral diet was pro-
gressively initiated, PPI was switched to oral formulation, and DAPT
was re-instituted under surveillance, with good tolerance. Oral iron
supplementation was initiated. The patient was discharged on the
eighth day after TAVI, clinically well. She was referred for short-term
outpatient clinic evaluation by Cardiology and Gastroenterology.
At follow-up, the patient remained without symptoms of heart
failure or related to ANE complications. Transthoracic echocardiog-
raphy evaluation 3 months after discharge showed maintenance of a
very slight leak in relation to the native right coronary cusp, with no
significant changes in all other parameters. Endoscopic reassessment
was not performed, since the previous showed good evolution and
the patient had no symptoms or signs of stenosis or relapsing
necrosis.
Discussion and conclusions
To the best of our knowledge, this is the first clinical case report to
describe the occurrence of ANE as a possible complication of TAVI.
There is a single case of isolated proximal black oesophagus reported
in a patient who underwent cardiac catheterization, an event that
was possibly related to the procedure.6
The ANE is an entity first described in 1990 by Goldenberg et al.7
It is a very rare disease, affecting men four times more commonly
than women, with undetermined incidence and is often under-
diagnosed; in endoscopic studies the prevalence of ANE ranges from
0.01% to 0.2%.8–10 The most frequent clinical manifestations are the
occurrence of upper gastrointestinal bleeding (90% of the cases),
haematemesis or melaenas, and chest pain.11–13 The usual triggering
factor is an episode of ischaemic insult—haemodynamic instability,
shock and/or hypoxia.14 Aggression or fragilization of the
oesophageal mucosa by internal or external factors, and the exist-
ence of associated medical comorbidities are recognized predispos-
ing factors.7–14 It has a typical endoscopic presentation, previously
described in this case, primarily affecting the distal region of the oe-
sophagus, which is related to the scarce vascularity of this region.14
Biopsy is usually unnecessary, but it can be performed specially when
it is important to make a differential diagnosis with melanoma, acan-
thosis nigricans, and pseudo-melanosis of the oesophagus. Treatment
of ANE should focus on supportive care to maximize organ perfu-
sion, treatment of underlying medical conditions, and intravenous
PPI. Adequate monitoring to detect and properly treat complications
is also essential.15
The importance of recognition of this entity is related to the high
rate of acute and long-term complications—occurrence of trans-
mural necrosis with perforation, mediastinitis, mediastinal abscess,
sepsis, and oesophageal stenosis (10–25% at long-term follow-up).
Mortality depends on the underlying condition and it is variably
reported in the literature, between 6% to as high as 36%, when asso-
ciated with other comorbidities.10,12 There are limited data to guide
the management of ANE, and it is largely based upon clinical experi-
ence. Repeat endoscopic evaluation should be done to assess muco-
sal healing. With supportive care, resolution of endoscopic findings
occurs in most patients within 72 h to 2 weeks. Symptoms of oe-
sophageal stenosis should be monitored in the long term.16
In this clinical case, the transient low output state during TAVI was
probably the ischaemic insult that triggered ANE. The period of
hypotension was short (<4 min), without evidence of other end-
organ hypotensive damage. However, the insult of TOE during TAVI
and DAPT may have led to oesophageal mucosa fragilization, making
it especially vulnerable to the ischaemic injury. Patient’s age, frailty
and diffuse atherosclerotic disease are additional predisposing factors
of ANE. The reason why this specific patient had this manifestation,
when most TAVI patients share these risk factors, is not known. The
use of conscious sedation, with local anaesthesia and TTE guidance,
could minimize the risk of this complication, avoiding the additional
aggression of the oesophageal mucosa by the TOE probe.
Figure 3 Endoscopy control study showing resolution of the previously described lesions.
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..In addition to demonstrating, for the first time, the occurrence of a
rare complication with a possible association with TAVI, this clinical
case is also paradigmatic and exemplary of the importance of the
multidisciplinary approach of these complex patients that extends
even beyond the concept of the Heart Team.
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